This was a positive announcement, once they get this approval that opens up another 20% revenue in Europe and we already know CUV in EPP has another 97/98% target market to get treated.
Plenty in this one trick pony in Revs and profit until they roll out further indications and the OTC.
Ann: CLINUVEL submits label expansion for adolescent EPP patients, page-11
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.17 |
Change
0.080(0.57%) |
Mkt cap ! $709.3M | |||
| Open | High | Low | Value | Volume |
| $14.02 | $14.28 | $13.94 | $860.1K | 60.89K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 685 | $14.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.20 | 3 | 1 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| CUV (ASX) Chart |